Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b

Barinthus Biotherapeutics plc.

IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.
HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.
In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.
Both regimens were generally well tolerated with no treatment-related SAEs reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.